^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CLN-617
i
Other names: CLN-617
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Cullinan Therap
Drug class:
IL-2 stimulant, IL-12 stimulant
Related drugs:
7ms
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=86, Recruiting, Cullinan Oncology, LLC | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • CLN-617
8ms
A phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 fusion protein) combined with pembrolizumab in patients with advanced solid tumors (SITC 2023)
Secondary endpoints involve the assessment of pharmacokinetics, pharmacodynamics, and immunogenicity across the 3 parts of the trial. Patients’ enrollment is currently ongoing, and updates will be provided at the time of the presentation.
Clinical • P1 data • PK/PD data • Metastases
|
IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • CLN-617
Share via
